Martin Shkreli wants you to swallow his bitter pill — and to thank him for making you pay $750 for it.
For 62 years, the drug Daraprim has been the standard method to treat parasitic infections that are particularly life-threatening to AIDS and cancer patients. It was relatively affordable — though low-income patients might take issue with calling an $18 pill “affordable” — and highly effective in treating these infections.
Then last month, Shkreli and his company, Turing Pharmaceuticals, came along and acquired rights to the drug. Their contribution to better the lives of these patients?
Jacking up the price 4,000 percent. Read more